High Note Wealth’s United Therapeutics UTHR Stock Holding History

High Note Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17	Closed	-$6K	–	967
2024 Q4	$6K	Buy	+17	New	+$6.25K	﹤0.01%	378

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

High Note Wealth's UTHR Position: Q1 2025 in Review

High Note Wealth sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 17 shares — an estimated $6K sold.

High Note Wealth first reported a position in UTHR in Q4 2024 and held it in 1 quarter. The position peaked at $6K in Q4 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

High Note Wealth reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
High Note Wealth sold 17 United Therapeutics shares in Q1 2025, an estimated $6K.
High Note Wealth first reported a position in United Therapeutics in Q4 2024 and held it in 1 quarter.
High Note Wealth's United Therapeutics position peaked at $6K in Q4 2024.
671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on High Note Wealth's 13F filing for Q1 2025, filed 1 May 2025.